AprilBio Receives Phase 1 Clinical Trial Approval for Autoinflammatory Disease Treatment in Australia
[Asia Economy Reporter Jang Hyowon] April Bio announced on the 16th that it has received approval from the Australian Human Research Ethics Committee (HREC) for the Phase 1 clinical trial of its autoinflammatory disease treatment candidate 'APB-R3'.
In Phase 1, the pharmacokinetic properties, safety, and immunogenicity of the candidate substance will be evaluated in 31 healthy adults aged between 18 and 60.
According to April Bio, APB-R3 is a protein drug that incorporates technology to extend the time the antibody substance remains in the body, thereby enhancing the duration of its efficacy. Previous animal experiments using mice demonstrated its anti-inflammatory effects.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Will Soaring Semiconductor Prices Support a Gradual Stabilization of the Household Debt Ratio? Why [BOK Focus]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
April Bio, a company developing antibody drugs, submitted the Phase 1 clinical trial plan for this candidate substance in Australia last month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
